Quantcast
Home > Quotes > SRPT
x
SRPT

Sarepta Therapeutics, Inc. Common Stock (DE) (SRPT) Quote & Summary Data

$139.32
*  
0.52
0.37%
Get SRPT Alerts
*Delayed - data as of Oct. 19, 2018 10:14 ET  -  Find a broker to begin trading SRPT now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    SRPT Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 139.23 / $ 139.59
1 Year Target
200
Today's High / Low
$ 140.03 / $ 137.19
Share Volume
50,487
50 Day Avg. Daily Volume
1,108,687
Previous Close
$ 138.80
52 Week High / Low
$ 176.50 / $ 46.07
Market Cap
9,256,755,447
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -3.37
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.43

Intraday Chart

Shares Traded

Share Volume:
50,487
50 Day Avg. Daily Volume:
1,108,687

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -3.37

Trading Range

The current last sale of $139.32 is 202.41% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 140.03 $ 176.50
 Low: $ 137.19 $ 46.07

ETFs with SRPT as a Top 10 Holding*

Weighting ETF Name (Symbol) 100-Day Price Change (%)
2.6% Principal Healthcare Innovators Index ETF (BTEC) +2.09 (6.63%)
1.48% Principal Sustainable Momentum Index ETF (PMOM) N/A (N/A)
1.28% iShares Morningstar Small-Cap Growth ETF (JKK) -1.64 (-0.84%)
0.48% John Hancock Multifactor Small Cap ETF (JHSC) -0.72 (-2.69%)
0.34% SPDR Portfolio Small Cap ETF (SPSM) -1.19 (-3.74%)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.

Company Description (as filed with the SEC)

We are a commercial-stage biopharmaceutical company focused on helping patients through the discovery and development of unique RNA-targeted therapeutics, gene therapy and other genetic medicine approaches for the treatment of rare neuromuscular diseases. Applying our proprietary, highly-differentiated and innovative RNA-targeted platform technologies, we are able to develop candidate therapies for a broad range of diseases and disorders. Our first commercial product in the U.S., EXONDYS 51, was granted accelerated approval by the FDA on September 19, 2016. EXONDYS 51 is indicated for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. A summary description of our product and main product candidates is as follows: * EXONDYS 51, our first product, uses our PMO chemistry and exon-skipping technology to skip exon 51 of the dystrophin gene.  ... More ...  


Risk Grade

Where does SRPT fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 139.68
Open Date:
Oct. 19, 2018
Close Price:
N/A
Close Date:
N/A

Consensus Recommendation

Analyst Info